Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients. - Wikidata - awgldk - TriplyDB

Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients.

Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients.

http://www.wikidata.org/entity/Q37128664

about

The Role of Immunotherapy in Multiple Myeloma Interleukin 12: still a promising candidate for tumor immunotherapy?Clinical trials of dendritic cell-based cancer vaccines in hematologic malignancies New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)Harnessing immunosurveillance: current developments and future directions in cancer immunotherapy Cancer vaccines Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma Development of Novel Immunotherapies for Multiple Myeloma Extracellular vesicle cross-talk in the bone marrow microenvironment: implications in multiple myeloma Identification and expression of MMSA-8, and its clinical significance in multiple myeloma.Back to the future! The evolving role of maintenance therapy after hematopoietic stem cell transplantation.NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma.Blood and marrow transplant clinical trials network state of the Science Symposium 2014 Haematological malignancies: at the forefront of immunotherapeutic innovation.Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells.Utilizing cell-based therapeutics to overcome immune evasion in hematologic malignancies.CMRF-56(+) blood dendritic cells loaded with mRNA induce effective antigen-specific cytotoxic T-lymphocyte responses.Dendritic cells in cancer immunotherapy clinical trials: are we making progress?The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.Immunotherapeutic approaches to treat multiple myeloma Immunotherapy for multiple myeloma.Current treatment landscape for relapsed and/or refractory multiple myeloma.Beyond consolidation: auto-SCT and immunotherapy for plasma cell myeloma.Impact of the immune system and immunotherapy in colorectal cancer.Preclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myeloma.Immunotherapy for Multiple Myeloma, Past, Present, and Future: Monoclonal Antibodies, Vaccines, and Cellular Therapies.Update on Mucin-1 immunotherapy in cancer: a clinical perspective.The impact of dendritic cell-tumor fusion cells on cancer vaccines - past progress and future strategies.Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1.Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.Role of the Immune Response in Disease Progression and Therapy in Multiple Myeloma.Vision Statement for Multiple Myeloma: Future Directions.Challenges in vaccine therapy in hematological malignancies and strategies to overcome them.Targeting Intrinsic and Extrinsic Vulnerabilities for the Treatment of Multiple Myeloma.MUC1 in hematological malignancies.Extracellular matrix and the myeloid-in-myeloma compartment: balancing tolerogenic and immunogenic inflammation in the myeloma niche.Review on the immunotherapy strategies against metastatic colorectal carcinoma.Is immunotherapy here to stay in multiple myeloma?Mechanisms of Resistance in Multiple Myeloma.Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies.

P2860

Q26771144-8C27C03F-48A5-4FF1-A313-F7332E9F82DD Q26861559-5587AAD5-120C-4EBE-8FB8-9FFCFCDA63DD Q26864603-0F5B7311-8704-4C43-BAC7-352EFFE9E38F Q27004421-C06B44E3-094C-4144-AD35-94FE70593590 Q27021570-668C5C59-12B3-4C60-A893-8351EB9673B2 Q27024438-A4FFDE2C-267A-4EB9-9A3D-A6CC904D61C9 Q27027729-5056FA30-1861-4659-8A60-E95D29384CA7 Q28066890-904BD3D2-737A-4BCE-B8A9-94E09254629B Q28077635-5CCB1ED5-3CEC-4079-BE0F-4F70F95E197B Q33721123-2B427C88-314C-4278-A4E9-2B556B0B2941 Q34380489-9B80ED68-57A4-49CA-B6C1-324A93075901 Q34485950-3B44F2A0-20DD-41A1-9124-C6CDCCAE7158 Q35591760-C70D81EA-7336-4C04-BC40-F550BB82272E Q35880618-C915B8D9-4ED3-498B-A16C-723ABCDDE27F Q36018407-A05B296A-000B-481D-8830-EC9C1E64171E Q37058110-696E27E5-9D4A-4F50-8743-ABD4A27728B6 Q37078990-0EC8831B-EACB-4FA1-8013-0AAB290C17FE Q37389096-BEBA28CA-156E-4D6B-8ECC-F7A57E80B87D Q37517482-C7AF3070-8A0C-4125-8845-6A264456A9D1 Q38171067-D5DD8812-F909-4B02-B880-C1F38CCDB9C6 Q38177879-2D03DC97-A3F2-4AAB-937B-B70D8BB8EB22 Q38271032-986858AE-7B30-4456-9146-54AE942D70DD Q38370539-4DA0C9E2-446D-4ACE-A448-55032039363A Q38398877-65D2B640-3F89-4609-A141-8CEF2234B803 Q38526452-121C833B-2BFB-4376-8C62-330366C7BA6E Q38580545-0C1D605C-CCAA-48B7-B7F5-161C6456B92A Q38603410-83792B2A-B15A-47AE-88DC-6DA64A2F1FA4 Q38617733-33FBC305-2686-4B25-B0A2-DBCA0460836F Q38720340-B0704151-94E7-4E2A-9C2C-D4B4CDC09929 Q38792725-18487FC4-1BB9-44D0-B7B3-4999519DC79E Q38815399-C22431E6-0BB7-4BFD-AFFF-EC0007F12E60 Q38815409-B0AD3CA6-2EE1-4D0E-AE0D-ECC3ECB8D37F Q38843235-E710B5ED-375D-4150-B62B-BE89C0363DDE Q38853857-595ABEF1-F1D3-4D67-804A-2478BF466673 Q38878148-5639913C-5FD3-4AE3-889C-4B4757F6230C Q38932298-920ADFD5-33C6-438D-8A38-80C2E60A5F5D Q38948909-D90E1028-F9B0-41BF-829F-DC89DA9623C7 Q39084427-BD8D96B5-C79C-4128-8C03-E208C1AD18B1 Q39185604-6EE5D615-7A79-4819-8E75-77B2F0493E9F Q39243052-B114F246-15E3-4AC3-AC9E-2227AB474D8F

P2860

Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients.

http://www.wikidata.org/entity/Q37128664

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 17 May 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Vaccination with dendritic cel ...... in multiple myeloma patients.

@en

Vaccination with dendritic cel ...... in multiple myeloma patients.

@nl

type

label

Vaccination with dendritic cel ...... in multiple myeloma patients.

@en

Vaccination with dendritic cel ...... in multiple myeloma patients.

@nl

prefLabel

Vaccination with dendritic cel ...... in multiple myeloma patients.

@en

Vaccination with dendritic cel ...... in multiple myeloma patients.

@nl

P1433

Q37128664-DD13C508-8B26-4555-9054-35AE48DDE0C2

P1476

Q37128664-098CE97C-EA89-43AA-851A-9B222993DAAB

P2093

Q37128664-0599C24E-8F51-48B3-BE7A-292671DC3DB4

Q37128664-0A0CFC7C-8B4F-441D-909B-33497D41AC41

Q37128664-21DB7794-16E0-4F70-A73A-8192A9F3C90B

Q37128664-2E8CAAAA-5930-4B0F-A21C-31393778E327

Q37128664-34B92D97-5386-484C-BF9E-D70ECA441B2A

Q37128664-4220FB69-9382-4DE3-B470-A8E6E3603120

Q37128664-54EDB9B7-69E0-4981-AB00-62FF338B00D6

Q37128664-557A75A1-DAD9-497D-8E38-A5A3A853E60E

Q37128664-5FA37771-EBE2-453E-BEDF-9A7E88B50AA9

Q37128664-62B921B1-6F6C-4901-8BE2-2AAA70A8320F

P2860

Q37128664-16049FB9-7AB8-4542-82F5-6B2DAD4140A8

Q37128664-1EBFE262-CFBE-4EB9-935F-78AD7556B0DE

Q37128664-433E2BDF-6904-4979-BBC6-8248785B6796

Q37128664-476C7695-BE59-4B8E-BCD5-B09F036B9BFB

Q37128664-47F6A555-6648-47E8-BCDA-BF127494034A

Q37128664-50075BCB-5B9B-4098-988F-05651C833D2C

Q37128664-53D6C4AE-EEFC-4F51-944D-A80C0989D6C6

Q37128664-686BE243-A4A3-4A7D-BC70-1B2B695F2BEE

Q37128664-7638CC51-2440-40C5-83DE-18DC84EC9630

Q37128664-8671AE10-42C3-462B-B2A2-83B632A97DAE

P304

Q37128664-B3DDBDFC-4D0B-4C66-BAAE-A07809B21A08

P31

Q37128664-2B83EF7C-D41A-426F-A83E-60399C718346

P356

Q37128664-441A44ED-739E-40E8-813F-B7424E7E6D83

P407

Q37128664-945CFE68-2E7D-4488-9AFF-AF45C3CCBF90

P433

Q37128664-CDAB943B-8A8B-4074-A9B6-D51306582955

P478

Q37128664-2E5C4FAC-1E83-41A2-8DE4-1FBBD36013F2

P50

Q37128664-DE328E4D-5AD9-4A82-9BDB-D8F339504A63

Q37128664-F79CFE05-7A1C-4D41-8678-4F5F8D4BD7F3

P577

Q37128664-AAA8C992-392D-4D94-8662-4ED5D72146BE

P5875

Q37128664-F2D58189-80C3-45B4-BCD2-CBF05EB6625A

P698

Q37128664-5C976F1E-CEFA-4AE6-BB53-14E941E31A0F

P921

Q37128664-36FC6540-3403-47F8-9664-55791DBB07C1

P932

Q37128664-6B3016AF-C749-4F18-9629-09AE50A8A9F4

P356

1078-0432.CCR-13-0282

P1433

Clinical Cancer Research

P1476

Vaccination with dendritic cel ...... in multiple myeloma patients.

@en

P2093

Baldev Vasir

http://www.w3.org/2001/XMLSchema#string

Bimalangshu R Dey

http://www.w3.org/2001/XMLSchema#string

David Avigan

http://www.w3.org/2001/XMLSchema#string

Dimitrios Tzachanis

http://www.w3.org/2001/XMLSchema#string

Donald Kufe

http://www.w3.org/2001/XMLSchema#string

Edie Weller

http://www.w3.org/2001/XMLSchema#string

Federico Campigotto

http://www.w3.org/2001/XMLSchema#string

Heidi Mills

http://www.w3.org/2001/XMLSchema#string

Irit Avivi

http://www.w3.org/2001/XMLSchema#string

Jacalyn Rosenblatt

http://www.w3.org/2001/XMLSchema#string

P2860

PD-1 and its ligands in tolerance and immunity

Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens.

Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma

Lenalidomide after stem-cell transplantation for multiple myeloma

International uniform response criteria for multiple myeloma.

A comparison of allografting with autografting for newly diagnosed myeloma.

Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells.

T cell immune reconstitution following lymphodepletion.

NY-ESO-1 immunotherapy for multiple myeloma.

Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules.

P304

3640-3648

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-13-0282

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P50

Kenneth C Anderson

Paul G Richardson

P577

2013-05-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236920240

http://www.w3.org/2001/XMLSchema#string

P698

23685836

http://www.w3.org/2001/XMLSchema#string

P921

P932

3755905

http://www.w3.org/2001/XMLSchema#string